Denise ScotsKnight - Elanco Animal Independent Director
| ELAN Stock | USD 13.13 0.26 1.94% |
Director
Dr. Denise ScotsKnight is Independent Director of the company. Dr. ScotsKnight has served as a member of the Board since March 2019. Dr. ScotsKnight was the cofounder of, and has served as the Chief Executive Officer and member of the board of Mereo BioPharma Group plc, a specialty biopharmaceutical company, since 2015. From 2010 until 2015, she was the Managing Partner of Phase4 Partners Ltd., a global life science VC firm. From 2004 to 2010, Dr. ScotsKnight was head of Nomura Phase4 Ventures, a VC affiliate of Nomura International plc, a leading Japanese financial institution. Dr. ScotsKnight has served on the boards of directors of Oncomed Pharmaceuticals, Inc., Idenix Pharmaceuticals, Inc. and Nabriva Therapeutics AG. Ms. Scots Knights experience described above, including her extensive previous board leadership, history leading an innovation and growthoriented company, and expertise building innovation models and partnerships, provides her with the qualifications and skills to serve as a director on Elancos board. since 2019.
| Age | 61 |
| Tenure | 5 years |
| Address | 2500 Innovation Way, Greenfield, IN, United States, 46140 |
| Phone | 877 352 6261 |
| Web | https://www.elanco.com |
Elanco Animal Management Efficiency
The company has return on total asset (ROA) of 0.0118 % which means that it generated a profit of $0.0118 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0324 %, meaning that it created $0.0324 on every $100 dollars invested by stockholders. Elanco Animal's management efficiency ratios could be used to measure how well Elanco Animal manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of November 2024, Return On Capital Employed is likely to grow to 0.03, though Return On Tangible Assets are likely to grow to (0.24). As of the 28th of November 2024, Asset Turnover is likely to grow to 0.33, while Total Assets are likely to drop about 13.6 B.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Jack Stahl | Catalent | 67 | |
| James Jenness | Prestige Brand Holdings | 73 | |
| Sheila Hopkins | Prestige Brand Holdings | 64 | |
| Perry Nisen | Teva Pharma Industries | 64 | |
| Donald Morel | Catalent | 63 | |
| Julie McHugh | Ironwood Pharmaceuticals | 60 | |
| Rolf Classon | Catalent | 75 | |
| Peter Zippelius | Catalent | 41 | |
| Roberto Mignone | Teva Pharma Industries | 48 | |
| Dawn Allen | Haleon plc | 56 | |
| Rosemary Crane | Teva Pharma Industries | 60 | |
| Philip CFA | Prestige Brand Holdings | N/A | |
| JeanMichel Halfon | Teva Pharma Industries | 68 | |
| Gregory Lucier | Catalent | 56 | |
| Gerald Lieberman | Teva Pharma Industries | 73 | |
| Dawn Zier | Prestige Brand Holdings | 55 | |
| Matt Roache | Ironwood Pharmaceuticals | N/A | |
| Natale Ricciardi | Prestige Brand Holdings | 71 | |
| Christa Kreuzburg | Catalent | 61 | |
| Gary Costley | Prestige Brand Holdings | 55 | |
| John Greisch | Catalent | 65 | |
Management Performance
| Return On Equity | 0.0324 | ||||
| Return On Asset | 0.0118 |
Elanco Animal Health Leadership Team
Elected by the shareholders, the Elanco Animal's board of directors comprises two types of representatives: Elanco Animal inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Elanco. The board's role is to monitor Elanco Animal's management team and ensure that shareholders' interests are well served. Elanco Animal's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Elanco Animal's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jose Simas, Executive Vice President U.S. Farm Animal Business | ||
| Timothy Bettington, Executive Development | ||
| Joshua Smiley, Independent Director | ||
| Chris Keeley, Senior Officer | ||
| Carl McMillian, Independent Director | ||
| Katy Grissom, Head Relations | ||
| Ellen Brabander, Executive Vice President - Innovation and Regulatory Affairs | ||
| Sarena Lin, Executive Vice President, Global Marketing, Corporate Strategy and Transformation | ||
| Paul Herendeen, Independent Director | ||
| Racquel Mason, Executive Vice President and Chief Marketing Officer, Elanco Animal Health | ||
| Rajeev Modi, Executive Vice President - U.S. Pet Health and Global Digital Transformation | ||
| Jeffrey Simmons, President, Chief Executive Officer, Director | ||
| Denise ScotsKnight, Independent Director | ||
| David Kinard, Executive Vice President, Human Resources, Corporate Affairs and Administration | ||
| David Urbanek, Executive Vice President - Manufacturing, Quality | ||
| Aaron Schacht, Executive Vice President, Innovation, Regulatory and Business Development | ||
| R Hoover, Independent Chairman of the Board | ||
| Larbi Lier, Senior Asia | ||
| Kirk McDonald, Independent Director | ||
| James Meer, Senior Vice President, Chief Accounting Officer | ||
| Art Garcia, Independent Director | ||
| Shiv ONeill, General President | ||
| Joyce Lee, Executive Vice President and President U.S. Pet Health and Commercial Operations | ||
| Kapila Anand, Independent Director | ||
| Michael Harrington, Independent Director | ||
| Todd Young, Chief Financial Officer, Executive Vice President | ||
| David Ricks, Independent Director | ||
| Marcela Kirberger, Executive Vice President General Counsel, Company Secretary | ||
| Scott Ferguson, Independent Director | ||
| Shawn McKee, Sr Animal | ||
| Deborah Kochevar, Independent Director | ||
| Lawrence Kurzius, Independent Director | ||
| Ramiro Cabral, Executive Vice President - Elanco International and Global Customer Value | ||
| Aarti Shah, Independent Director | ||
| Dirk Ehle, Executive Vice President and President Elanco Europe | ||
| William Doyle, Independent Director | ||
| John Bilbrey, Independent Director | ||
| Todd JD, Executive CFO |
Elanco Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Elanco Animal a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0324 | ||||
| Return On Asset | 0.0118 | ||||
| Profit Margin | 0.05 % | ||||
| Operating Margin | (0) % | ||||
| Current Valuation | 10.36 B | ||||
| Shares Outstanding | 494.35 M | ||||
| Shares Owned By Insiders | 0.65 % | ||||
| Shares Owned By Institutions | 98.94 % | ||||
| Number Of Shares Shorted | 15.16 M | ||||
| Price To Earning | 241.75 X |
Pair Trading with Elanco Animal
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Elanco Animal position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Elanco Animal will appreciate offsetting losses from the drop in the long position's value.Moving together with Elanco Stock
Moving against Elanco Stock
| 0.78 | LPCN | Lipocine | PairCorr |
| 0.78 | PHVS | Pharvaris BV | PairCorr |
| 0.59 | GILD | Gilead Sciences | PairCorr |
| 0.55 | PLRX | Pliant Therapeutics | PairCorr |
| 0.49 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
The ability to find closely correlated positions to Elanco Animal could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Elanco Animal when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Elanco Animal - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Elanco Animal Health to buy it.
The correlation of Elanco Animal is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Elanco Animal moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Elanco Animal Health moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Elanco Animal can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Elanco Animal Health. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Elanco Animal. If investors know Elanco will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Elanco Animal listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.71) | Earnings Share 0.41 | Revenue Per Share 9.023 | Quarterly Revenue Growth (0.04) | Return On Assets 0.0118 |
The market value of Elanco Animal Health is measured differently than its book value, which is the value of Elanco that is recorded on the company's balance sheet. Investors also form their own opinion of Elanco Animal's value that differs from its market value or its book value, called intrinsic value, which is Elanco Animal's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Elanco Animal's market value can be influenced by many factors that don't directly affect Elanco Animal's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Elanco Animal's value and its price as these two are different measures arrived at by different means. Investors typically determine if Elanco Animal is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Elanco Animal's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.